Tidifar

Cimetidine

Method of action: Antiulcer, Drugs For Acid Related Disorders

Treatment option: Pain, Abdominal pain, Reflux, Reflux Esophagitis, Zollinger-Ellison Syndrome, Short Bowel Syndrome, Stress, Esophagitis, Peptic Ulcer

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tidifar

Property	Description
Active ingredient	Cimetidine
Form	Tablets, oral solution, solution for injection
Pharmacological class	Histamine H2-receptor antagonist (H2RA)
General purpose	Reduction of gastric acid secretion
Origin	Synthetic drug

Tidifar is a medicine containing the single active ingredient Cimetidine, which is classified as a Histamine H2-receptor antagonist (H2RA). Cimetidine is a synthetic drug, an Imidazole derivative, that is clinically recognized as one of the earliest compounds developed specifically for targeted gastric acid management. This first-generation H2RA differs from its successors primarily through its initial development history, pioneering the selective receptor blocking mechanism, a process supported by numerous pharmacological studies.

Composition and Available Pharmaceutical Forms

Tidifar is manufactured as a single-ingredient product, consisting solely of Cimetidine combined with necessary pharmaceutical excipients or an aqueous vehicle. It is widely available in several dosage forms, most commonly as tablets and an oral solution for oral administration. The medicine is also formulated as a sterile solution for injection, allowing it to be administered parenterally via injection or infusion to achieve a systemic effect when the oral route is not suitable.

General Purpose: How Tidifar Addresses Gastric Acidity

The primary therapeutic purpose of Tidifar is to assist in the management and relief of discomfort associated with excess stomach acid. The drug operates by causing a targeted reduction of stomach acid secretion, thus diminishing the volume and acidity of gastric fluid within the stomach. Cimetidine reduces both the basal and stimulated output of gastric acid. This action provides foundational relief for individuals experiencing symptoms of irritation and burning in the upper digestive tract by mitigating the corrosive presence of stomach acid.

Regulatory References

NIH MedlinePlus Drug Information

What side effects are possible with Tidifar?

Possible Side Effects and Safety Information

The safety profile of Tidifar, which contains the active ingredient Cimetidine, is organized in regulatory documents by the System-Organ-Class (SOC) affected and the officially documented frequency of the adverse reaction. The most commonly reported side effects, classified as Common (1% to 10%), typically involve the nervous system and gastrointestinal tract, including headache, dizziness, drowsiness, diarrhea, and constipation. Laboratory findings, such as an increase in plasma creatinine, are documented as a Very Common occurrence.

Documented Adverse Reactions and Patterns

Adverse reactions classified as Uncommon or Rare include effects on the blood and lymphatic system (e.g., leukopenia, thrombocytopenia) and the hepatobiliary system (e.g., reversible liver damage, hepatitis). Rarer events classified as Serious Adverse Reactions in official labeling include agranulocytosis, aplastic anemia, pancreatitis, and severe hypersensitivity reactions such as anaphylaxis.

Time-related patterns are noted for certain effects: confusional states often develop within the first few days of treatment initiation, while sexual and endocrine effects, such as reversible impotence and gynecomastia, are associated with use for one month or longer.

Population-Specific Safety Considerations

The regulatory labeling highlights specific safety considerations for certain patient groups. Older adults and individuals with impaired renal function are noted to have an increased potential for developing confusional states. Furthermore, the official labeling includes the important restriction that symptomatic improvement during treatment does not exclude the presence of an underlying gastric malignancy.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Tidifar

Suspected overdose with Cimetidine (Tidifar) requires immediate emergency medical attention and contact with the Poison Help line, as explicitly stated in regulatory prescribing information.

Documented Manifestations and Severe Outcomes

Overdose presentations documented in official sources include specific signs such as tachycardia (rapid heart rate) and dyspnea (shortness of breath). The regulatory profile also notes the potential for compromised cardiovascular status and airway, defining a risk that may lead to respiratory failure in severe cases. Furthermore, clinical observations of the H2-receptor antagonist class include central nervous system effects such as confusion, drowsiness, or low blood pressure.

Emergency Management and Monitoring

Management procedures described in official labels confirm that there is no specific antidote for Cimetidine overdose. Treatment is restricted to providing symptomatic and supportive treatment. Required procedural steps include measures for gastric decontamination to clear unabsorbed drug from the gastrointestinal tract, and the use of artificial respiration if respiratory function is compromised. Patients must be closely monitored for changes in vital signs and systemic function. Regulatory documents further note that patients who are elderly or have pre-existing renal or hepatic disease may be more susceptible to serious adverse events like CNS effects, requiring heightened observation in an overdose context.

Therapeutic Uses of Tidifar

What Tidifar Treats: Main Uses and Benefits

The primary role of Tidifar may be part of symptomatic management and is commonly used to help with symptoms related to physical discomfort. It is generally used for managing symptoms that interfere with daily comfort during acute or episodic changes. The use of symptomatic relief as a therapeutic strategy is broadly referenced in official health information.

Tidifar is commonly applied across conditions presenting with acute episodes when manifestations become suddenly intense. It supports the patient by helping to manage the intensity of symptoms that may be disruptive, providing relief that assists with maintaining functional stability. Tidifar is relevant in contexts marked by increased discomfort or tension, including situations involving recurrent, episodic, or fluctuating manifestations.

“The goal is to provide supportive relief during symptomatic flare-ups, helping patients cope more steadily.”

Quick Fact: Relevant for easing symptoms related to heightened physiological activity

This medicine is considered relevant in clinical settings where symptoms create noticeable functional strain and interfere with daily comfort, particularly during phases when symptoms become temporarily overwhelming.

Eligibility and Restrictions for Use

The eligibility for using Tidifar (Cimetidine) is strictly defined by regulatory authorities based on population status, known allergies, and specific health conditions.

Contraindicated Populations

Tidifar must not be used by individuals with a documented hypersensitivity or allergy to Cimetidine or to any other medicine in the same class (H2-receptor antagonists). Use is also functionally contraindicated when taken with certain prescription medications, such as Dofetilide.

Eligibility by Age and Organ Function

Population Group	Regulatory Eligibility Status
Children under 12 years	Not recommended for over-the-counter use without consulting a physician.
Older Adults (Typically ge 65)	Conditional use; caution is required due to an increased risk of specific adverse effects, particularly confusion.
Renal or Hepatic Impairment	Restricted use; requires medical supervision as Cimetidine is cleared by the kidneys and caution is advised for liver impairment.

Pregnancy and Lactation Status

Use during pregnancy is generally considered conditional, and the official label advises consulting a health professional before use. Cimetidine is secreted into breast milk, and its use is generally not recommended while breastfeeding unless deemed essential by a physician.

Comorbidity Constraints

Official regulatory documents require that serious underlying conditions, particularly signs of a gastric malignancy (e.g., trouble swallowing, vomiting blood, bloody or black stools), must be ruled out before initiating treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tidifar's interaction profile is officially documented around mechanisms that alter the plasma exposure of co-administered medicinal products. Formal contraindicated combinations are explicitly listed in regulatory labeling. These include Dofetilide and Pimozide, as co-administration may lead to significantly increased plasma concentrations and associated risks.

Metabolic and Clearance Effects

The most prominent documented interaction involves the inhibition of certain liver Cytochrome P450 (CYP) enzymes. This effect reduces the hepatic clearance of drugs metabolized by these enzymes, resulting in increased systemic exposure of substances such as Warfarin-type anticoagulants, Phenytoin, and Theophylline. Additionally, Tidifar competes for active transport in the kidney, which alters the renal clearance of certain co-administered medicines, a factor noted in patients with impaired renal function.

Absorption and Timing Constraints

Tidifar causes an increase in gastric pH, which affects the absorption of products requiring an acidic environment for proper dissolution. The absorption of substances like certain Azole Antifungals (e.g., Ketoconazole) is decreased by this mechanism. Official documentation specifies mandatory timing rules for this interaction: the Azole Antifungal must be administered at least two hours before Tidifar. Simultaneous administration with Antacids is also officially discouraged.

Mechanism of Action

How Tidifar Works

Tidifar's action is defined by two primary mechanistic domains that influence key physiological systems. The drug engages key regulatory systems at the cellular level to influence systems characterized by high secretory activity.

Modulation of Gastric Acid Secretion

This mechanism centers on the drug acting as a competitive antagonist at the Histamine H2 receptors found on the stomach's parietal cells. By blocking the natural signaling molecule histamine, Tidifar prevents the cascade that normally stimulates the secretion of gastric acid. This action initiates or suppresses signaling sequences that lead to the key physiological consequence of a reduction in the concentration and volume of acid secreted into the stomach.

Influence on Hepatic Processing Systems

Tidifar also engages mechanisms that influence regulatory feedback within pathways by temporarily acting as an inhibitor of specific Cytochrome P450 (CYP) enzymes in the liver. This secondary domain affects systems where certain metabolic processes dominate, leading to a modification of early molecular steps in the processing of other substances. This inhibition influences the dynamics within the metabolic pathways, which can impact how long other compounds remain active in the body.

Dosage and Administration Information

How to Use Tidifar (Cimetidine): Official Administration Guidelines

Administration Scope

Tidifar (Cimetidine) is administered using specific routes and schedules defined in regulatory documents. The medicine is available for oral intake as tablets or oral solution, and for parenteral use as a solution for intravenous (IV) or intramuscular (IM) injection.

Standard dosing regimens typically involve a total daily dose of 800 mg, often taken once daily at bedtime for active therapy, or 400 mg twice daily. High-dose regimens can utilize up to 2400 mg per day, usually divided into doses taken with meals and at bedtime. For over-the-counter use in preventing heartburn, the dose is taken within 30 minutes before consuming symptom-triggering foods.

Procedural and Population-Specific Considerations

The treatment course is generally divided into short-term acute therapy (e.g., 4 to 8 weeks) followed by a lower-dose maintenance regimen (e.g., 400 mg at bedtime).

Dose reduction is mandatory for patients with impaired renal function, where the regimen is often adjusted to 300 mg every 12 hours. The dose is typically taken after dialysis in patients undergoing hemodialysis. When administering the IV injection, it must be delivered slowly over at least 2 to 5 minutes. If a scheduled dose is missed, the protocol is to skip that dose if it is near the time for the next dose, and not to double the amount.

Summary of Official Protocol

Regulatory instructions define a protocol where the administration route and frequency are dictated by the therapeutic goal, while the specific dose and timing are systematically adjusted based on a patient’s renal status and the overall phase of treatment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Tidifar (Cimetidine)

Evidence for Use in Active Duodenal Ulcer Disease

The research exploring the use of Cimetidine in duodenal ulcers primarily involved short-term Randomized Controlled Trials (RCTs), many of which were placebo-controlled and double-blind, alongside comparative trials and systematic meta-analyses. These pivotal studies typically included adults with confirmed ulcers. Researchers examined outcomes such as measured endoscopic endpoints and changes in patient-reported outcomes describing perceived discomfort, like daytime and nocturnal pain, comparing Cimetidine to a research control (placebo).

Studies reported measurements of measured endoscopic endpoints over defined short-term intervals, often spanning four to eight weeks. Trial findings describe patterns observed in the studies related to endpoints that were measured. Furthermore, longer-term research protocols also explored Cimetidine's use in studies examining long-term follow-up, monitoring how ulcer characteristics and patient-reported symptoms were tracked over extended periods.

Evidence for Use in Benign Gastric Ulcer

Research exploring benign gastric ulcers similarly relied on short-term Randomized Controlled Trials (RCTs), including placebo-controlled designs, and systematic reviews of these trials. These studies monitored endpoints related to physical healing, where endoscopic characteristics were tracked. Studies also examined how outcomes related to physical discomfort (pain and associated gastrointestinal symptoms) changed in the studied adults over the defined follow-up durations.

Areas of Research Uncertainty and Study Limitations

The research exploring the use of Cimetidine, particularly the pivotal trials, forms a large historical evidence base. However, evidence quality varies across studies, and limitations have been noted in authoritative reviews. For common conditions, the follow-up durations were limited in many primary RCTs, focusing only on short-term healing. Comparative evidence is lacking for direct, modern comparisons against newer drug classes for both short-term outcomes and long-term follow-up. Therefore, while research provides insight into short-term changes, the current scientific context requires consideration of when this evidence was observed in the studies.

Key Studies & References

Cimetidine Drug Information

Frequently Asked Questions (FAQ)

Common questions about Tidifar (FAQ)

Q: Is Tidifar considered a long-term medication?

A: Official information describes Tidifar's use for short-term acute therapy, often followed by a lower-dose maintenance regimen. Research has examined the use of maintenance therapy for up to five years in some patient populations, but the overall duration of use is defined by a healthcare professional.

Q: Are there any common over-the-counter medicines that interact with Tidifar?

A: Regulatory documents describe that the medicine has been associated with affecting the processing of certain compounds like Acetylsalicylic acid (Aspirin) and increasing the potential for certain effects with Acetaminophen (Tylenol). Official documents advise consulting a healthcare professional about all co-administered medications.

Q: What foods or supplements should be avoided while using Tidifar?

A: While official documents do not list specific forbidden foods, they do describe mechanisms that may affect how the body processes supplements. Regulatory sources advise consulting a healthcare professional about using this medicine with any nonprescription or herbal products like St. John's Wort, as interactions have been noted with co-administered medicines.

Q: What is the risk of stopping Tidifar suddenly?

A: Research has examined patterns where the sudden withdrawal of Tidifar resulted in the recurrence of severe symptoms in certain patient groups. Consequently, changes to the regimen are generally managed by a healthcare professional.

Q: What is the intended duration of treatment with Tidifar?

A: The intended duration is defined by the condition being addressed. For certain conditions, acute treatment is typically described as lasting 4 to 12 weeks, often followed by a lower-dose maintenance treatment phase. The overall length of treatment is managed by a healthcare professional based on the condition being treated.

Q: Can Tidifar be taken with high blood pressure medication?

A: Official interaction sections note that Tidifar can slow the metabolism of certain medicines commonly used for blood pressure management, including some beta-blockers and calcium channel blockers. Due to potential interactions, all current medications are reviewed by a healthcare professional.

Q: Is it normal to feel tired after starting Tidifar?

A: Official product information lists tiredness (fatigue) as one of the commonly reported side effects observed in clinical use. If tiredness persists or causes concern, official patient information advises speaking with a doctor or pharmacist.

Q: Is it safe to drink coffee while taking Tidifar?

A: Regulatory and pharmacological data indicate that Tidifar can potentially increase the blood levels of caffeine by decreasing the rate at which the body breaks it down. Official documents also note that the drug reduces gastric acid released in response to stimuli, including caffeine.

Q: Does Tidifar affect sleep patterns?

A: The safety profile documents effects on the central nervous system, which include dizziness and drowsiness. These effects may occur and could influence a patient’s normal sleep and wake cycles.

Q: Is Tidifar the same type of drug as [Competitor Drug Name]? (e.g., How does it compare to a similar drug?)

A: Tidifar, which contains Cimetidine, is classified as a Histamine H2-receptor antagonist (H2RA). This is a general class of medicine used to reduce the secretion of stomach acid, and other medications may fall into the same pharmacological class.

Q: How long can a person stay on Tidifar?

A: Official clinical evidence themes indicate that maintenance therapy has been continued for up to five years in some research settings. However, the exact duration of use is a clinical decision based on the individual patient's condition and management plan.

Q: What happens if a dose of Tidifar is missed?

A: Regulatory instructions clearly advise the patient to skip that dose if it is near the time for the next scheduled dose. It is strictly advised not to double the amount in an attempt to make up for the missed dose.

Q: Is Tidifar available as a generic version?

A: Official drug descriptions confirm that a generic version of Cimetidine is widely available. Generic medications contain the same active ingredient and meet the same regulatory quality standards as the brand-name product.

Q: Are there any lifestyle changes suggested when using Tidifar?

A: Official patient information often notes that for best results, the medication is often used alongside other practices. These may include general lifestyle changes such as stress-reduction programs, exercise, and diet changes.

Q: Are there research findings about Tidifar and long-term effects?

A: Longer-term research protocols have explored the use of Tidifar by examining long-term follow-up to monitor ulcer characteristics. However, authoritative reviews note that comparative evidence is lacking against newer drug classes for both short-term outcomes and long-term follow-up.

Q: Can Tidifar cause skin reactions or rashes?

A: Yes, official product information lists rashes as one of the commonly reported side effects in clinical use. If a rash or skin reaction develops, official patient information advises speaking with a healthcare professional.

Q: How does the body process or eliminate Tidifar?

A: Official pharmacokinetic data indicate that the active ingredient, Cimetidine, is primarily metabolized (or broken down) by the liver. The remaining drug is then eliminated from the body largely through the kidneys.

Q: Can Tidifar affect blood sugar levels?

A: Regulatory interaction data describes that Cimetidine can potentially increase the serum concentration of Acetohexamide, a drug used to manage blood sugar. Patients who take medication for diabetes are advised to consult their doctor regarding this interaction.

Q: What should I do if I think I'm experiencing a side effect from Tidifar?

A: Official patient information advises that if side effects persist or worsen, the patient should tell their doctor or pharmacist promptly. A doctor or pharmacist can provide assistance based on the reported side effect.

Q: What is the average time before Tidifar reaches its full effect?

A: The drug's official onset of action (when the effects begin) is typically reported to be around 30 minutes. However, the full therapeutic effect needed to heal conditions like ulcers is measured over a period of weeks.

Q: Can Tidifar be taken with aspirin?

A: Regulatory interaction data mentions that Cimetidine can decrease the excretion (removal) of Acetylsalicylic acid (Aspirin) from the body. This could result in a higher serum level of Aspirin, which may be a consideration depending on the total dose taken.

Q: What are the restrictions on driving or operating machinery while taking Tidifar?

A: Official warnings state that because the drug may cause dizziness or drowsiness, patients should use caution. Patients are advised to not drive, use machinery, or do any activity that requires alertness until they are certain they can perform such activities safely.

Q: Is Tidifar a controlled substance?

A: Official drug facts classify Cimetidine as Not a controlled medication.

Q: Are there any known issues with taking Tidifar on an empty stomach?

A: Official administration guidelines note that the drug is often prescribed to be taken at bedtime or with meals. The over-the-counter use for preventing heartburn is specifically taken within 30 minutes before consuming symptom-triggering foods, which may or may not be an empty stomach.

Q: Are there specific warnings for people with heart conditions using Tidifar?

A: Official warnings state that caution is required in patients with cardiopathy (heart disease), especially regarding the administration of the intravenous (IV) form. Direct IV injection is often advised to be avoided in patients suffering from cardiopathy.

Q: What is the process for discontinuing Tidifar?

A: Official documents and research often refer to the professional management of dose reduction. Because studies have explored that abrupt withdrawal can lead to a recurrence of severe symptoms in certain patients, discontinuation is typically managed by a healthcare professional due to the potential for symptom recurrence.

Q: What is the most serious, but rare, side effect associated with Tidifar?

A: Official labeling lists several serious but rare events. These include effects on blood cell production such as agranulocytosis and aplastic anemia, as well as severe immune reactions like anaphylaxis and life-threatening skin conditions such as Stevens-Johnson syndrome (SJS).

Q: Does the manufacturer of Tidifar offer an official patient information leaflet online?

A: Official regulatory sites, such as the FDA's Accessdata, publicly provide the full patient information leaflet and drug facts for Tidifar, which may be viewed or downloaded.

How should Tidifar be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling dictates specific conditions for storing and disposing of Tidifar (Cimetidine) to ensure product stability and safety.

Requirement Type	Official Labeled Condition
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Environmental Protection	Protect the product from moisture and light; liquid forms must not freeze.
Packaging	Keep the medicine in its original container and ensure it is tightly closed.
Child Safety	Store all forms of the medicine out of the sight and reach of children.
Disposal	Dispose of unused or expired product through an approved drug take-back program or according to local waste management regulations. Do not flush the product down a toilet or pour it down a sink.